11/12
11:33 am
tem
Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.
11/12
08:30 am
tem
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
Medium
Report
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
11/11
08:30 am
tem
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Medium
Report
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
11/11
08:08 am
tem
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.
11/9
05:11 am
tem
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/8
08:30 am
tem
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
High
Report
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
11/7
06:09 pm
tem
Tempus AI Inc (NASDAQ:TEM) Continues Strong Growth with 33% Revenue Increase, Price Target Raised to $56 [Yahoo! Finance]
High
Report
Tempus AI Inc (NASDAQ:TEM) Continues Strong Growth with 33% Revenue Increase, Price Target Raised to $56 [Yahoo! Finance]
11/7
04:47 pm
tem
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test [Yahoo! Finance]
High
Report
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test [Yahoo! Finance]
11/7
04:30 pm
tem
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
High
Report
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
11/7
08:38 am
tem
Exciting Growth Potential Ahead for Tempus AI (TEM) [Yahoo! Finance]
Low
Report
Exciting Growth Potential Ahead for Tempus AI (TEM) [Yahoo! Finance]
11/5
12:13 pm
tem
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates [Yahoo! Finance]
11/5
02:27 am
tem
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
11/4
04:45 pm
tem
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics [Yahoo! Finance]
Medium
Report
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics [Yahoo! Finance]
11/4
04:01 pm
tem
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
Medium
Report
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
11/3
08:06 pm
tem
Tempus to Report Third Quarter 2024 Financial Results on November 4
Medium
Report
Tempus to Report Third Quarter 2024 Financial Results on November 4
10/24
08:30 am
tem
Tempus to Report Third Quarter 2024 Financial Results on November 7
Low
Report
Tempus to Report Third Quarter 2024 Financial Results on November 7
10/15
08:47 am
tem
Tempus AI, Inc. (NASDAQ: TEM) had its price target raised by analysts at Loop Capital from $48.00 to $57.00. They now have a "buy" rating on the stock.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) had its price target raised by analysts at Loop Capital from $48.00 to $57.00. They now have a "buy" rating on the stock.
10/12
10:10 am
tem
Tempus AI, Inc (TEM): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Tempus AI, Inc (TEM): A Bull Case Theory [Yahoo! Finance]
10/2
08:08 am
tem
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $60.00 price target on the stock, up previously from $45.00.
Low
Report
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $60.00 price target on the stock, up previously from $45.00.
9/26
08:30 am
tem
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
Medium
Report
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
9/13
08:30 am
tem
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
Medium
Report
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
9/12
08:30 am
tem
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
Medium
Report
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
9/4
08:30 am
tem
Tempus Announces Real World Data Collaboration with BioNTech
Low
Report
Tempus Announces Real World Data Collaboration with BioNTech
8/28
08:30 am
tem
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
High
Report
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference